蒂尔福斯AG538通过TREM2主激素抑制血小板激活和血栓形成
相关实验视频
Updated: Jan 6, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
22.9K
Qian Liu1, Qingyuan Yang1, Yixian Wang1
1Department of Biopharmaceuticals, School of Pharmacy, Tianjin Medical University, China.
Biochemical pharmacology
|October 4, 2025
概括
蒂尔福斯AG538作为血小板TREM2受体激动剂,抑制血小板激活和血栓形成. 这种新型药物有效地减少了动脉血栓形成和肺栓塞,而不会增加出血风险.
科学领域:
- 心血管研究研究心血管研究
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉血栓性疾病对健康构成重大风险.
- 血小板在血栓形成中至关重要,它们的失调会导致出血或缺血事件.
- 目前的抗血小板疗法存在局限性,包括出血风险,需要新的药物来改善安全性.
研究的目的:
- 调查Tyrphostin AG538作为一种潜在的抗血小板剂.
- 为了确定AG538是否作为血小板上的TREM2受体的激动剂.
- 在血栓形成的临床前模型中评估AG538的疗效和安全性.
主要方法:
- 分子对接和表面等离子体共振 (SPR) 试验以确认AG538与TREM2.2结合.
- 使用TREM2淘汰赛小鼠血小板的实验.
- 在体外测试测量血小板聚合,密集颗粒释放,扩散和凝块收缩.
- 在体内研究涉及口服AG538在动脉血栓和肺栓塞的小鼠模型.
主要成果:
- AG538直接与TREM2受体结合.
- AG538抑制了人类和小鼠血小板的血小板聚合,密集颗粒释放,扩散和凝块收缩.
- 口服AG538抑制了原诱导的血小板激活,并显著减少了小鼠的动脉血栓形成和肺栓塞.
- AG538治疗没有增加出血风险.
- 在机械上,AG538抑制了TREM2下游的SHIP1-Akt通路.
结论:
- 蒂尔福斯AG538是一种新型血小板TREM2受体激动剂.
- AG538表现出强大的抗血小板和抗血栓作用,具有良好的安全性.
- AG538代表了一个有前途的治疗候选人,用于预防动脉血栓形成,减少出血并发症.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:00Enzyme-linked Receptors
85.5K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
85.5K
01:22Formation of the Platelet Plug
8.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
430
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
430
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K